The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
An article from
Dive Brief
//
Obesity drugs
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out…
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for…
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could…
A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could…
A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1…
